Early clinical trials for Chinese-developed COVID-19 vaccines have consistently shown promise by demonstrating safety and the ability to trigger significant immune responses. As of early 2026, China's vaccine landscape has evolved from traditional inactivated virus shots to innovative delivery methods, such as inhaled aerosols and mRNA technologies.
Early-stage trials for several Chinese candidates laid the foundation for global distribution: Covid-19: Chinese vaccine 'successful in mid-stage trials' Chinese COVID Vaccine Shows Promise in Early Trial